Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the appointment of Susan Abu-Absi, Ph.D., as ...

Quintet Private Bank Europe S.A. reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 8.8% in ...

The VanEck Morningstar Wide Moat ETF (MOAT) was launched on 04/24/2012, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity ...

Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

Plaintiffs lawyers seem to steer personal injury cases to the Philadelphia Common Pleas Court, and corporate defendants ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...